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Phthalates are commonly included as ingredients in personal care products such as cosmetics, 
shampoos and perfumes. Diethyl phthalate (DEP) has been found to be anti-androgenic and linked 
with adverse reproductive effects on males, but effects on females are poorly understood. We designed 
an integrative and translational study to experimentally examine the effects of DEP exposure at a 
human-equivalent dose on the mammary transcriptome in rats and to subsequently examine the DEP 
gene signature in breast tissues (both pre-malignant and tumor) from a population study. In Sprague-
Dawley rats treated orally with DEP from birth to adulthood, we identified a signature panel of 107 
genes predominantly down-regulated by DEP exposure. Univariate analysis of this 107 DEP gene 
signature in pre-malignant breast tissues revealed that six genes (P4HA1, MPZL3, TMC4, PLEKHA6, 
CA8, AREG) were inversely associated with monoethyl phthalate (MEP; the urinary metabolite of 
DEP) concentration (p < 0.05) among postmenopausal women; all six genes loaded on to one of seven 
factors identified by factor analysis. Transcription factor enrichment analysis revealed that genes in 
this factor were enriched for androgen receptor binding sites. These six genes were also significantly 
down-regulated in pre-malignant adjacent tissues compared to the corresponding tumor tissues in 
pair-wise analyses (p < 0.05). Results from our translational study indicate that low level exposure to 
diethyl phthalate results in measurable genomic changes in breast tissue with implications in breast 
carcinogenesis.
Phthalates are a family of chemicals with diverse properties that are added to a wide variety of consumer prod-
ucts and used in industrial and medical applications1. One of the congeners, diethyl phthalate (DEP), is com-
monly used as a plasticizer and solvent in personal care products such as cosmetics, shampoos and perfumes 
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and in pharmaceutical products1. The United States (U.S.) Food and Drug Administration found DEP to be the 
most common phthalate in personal care products2, a major source of exposure to DEP3. The urinary metabolite 
of DEP, monoethyl phthalate (MEP), is detectable in U.S. population samples at levels that are often an order 
of magnitude higher than other phthalates such as di(2-ethylhexyl) phthalate and dibutyl phthalate4. Due to 
non-covalent bonding to its parent materials, DEP is leached easily into the environment resulting in widespread 
human exposure1.
DEP has been shown to have anti-androgenic effects in males, including shorter anogenital distance5 and 
increased sperm DNA damage6,7. MEP has been detected in breast milk, suggesting lactational exposure, and 
was associated with lowered testosterone in infant males8. Links between phthalate exposures and female devel-
opmental and reproductive and cancer outcomes, however, have been less well studied, despite their potential as 
endocrine disruptors. Reduced fecundity with MEP exposure was reported in a Danish cohort9. An epidemio-
logic study in Mexican women showed an association between MEP exposure and increased breast cancer risk10. 
High serum level of MEP in postmenopausal women was associated with elevated breast density11, a marker for 
breast cancer risk12. We recently reported results from the Long Island Breast Cancer Study Project (LIBCSP) in 
which we did not observe any significant associations between urinary level of MEP and breast cancer risk, while 
inverse associations were observed for mono(3-carboxypropyl) phthalate (MCPP) and monocarboxyoctyl phtha-
late (MCOP), metabolites of anti-androgenic phthalates13.
Breast cancer is considered a hormone-driven disease14. Given the hormone-disrupting properties of DEP 
and its widespread exposure through the use of personal care and consumer products, there is an urgent need 
to systematically study whether DEP exposures may impact breast cancer development. In rats, fetal and prepu-
bertal exposures to high doses of butyl benzyl phthalate led to changes in gene expression profiles of mammary 
glands15,16. Less is known about the effects of DEP exposure particularly at doses that are relevant to human 
exposure.
The aim of our present study is to employ an animal model to experimentally identify a gene signature of DEP 
exposure at a human-equivalent dose and to subsequently translate these findings to humans. We exposed female 
Sprague-Dawley (SD) rats to DEP orally from birth to adulthood at a dose that was previously shown to produce 
a urinary metabolite (MEP) level similar to that of the U.S. population17. We identified a DEP gene signature in 
normal developing mammary glands in SD rats, and subsequently examined this signature in pre-malignant and 
breast cancer tissues from a subsample of women who participated in a population-based study. The overall goal 
of the study is to examine whether human level exposure to DEP induces measurable transcriptomic changes 
in target tissues, thus shedding light on the possible causal relationship between phthalate exposure and breast 
cancer.
Materials and Methods
Test compound. Diethyl phthalate (DEP) (CAS # 84-66-2, lot # STBB0862V, 99% purity) was supplied in 
plastic containers (Sigma Aldrich, Italy). Olive oil, supplied in glass bottles (Montalbano Agricola Alimentare 
Toscana, Florence, lot # 111275, Italy), was used as the vehicle to prepare the dosing solution. The experimental 
oral dose was 0.1735 mg/Kg/day, which represented 1/10,000 the no observed adverse effect levels (NOAEL) of 
DEP18–20. DEP was stored in the dark at room temperature (20 °C). The solutions were prepared weekly on the 
basis of mean body weight of each group and were continuously stirred before and during the treatment. To 
minimize external contamination, olive oil and DEP were stored in glass containers and administered using 5 mL 
glass syringes. Biological samples were collected in polypropylene vials. Chemical analyses and stability testing 
have been described previously21.
Animal studies. Animal studies were carried out at Cesare Maltoni Cancer Research Centre/Ramazzini 
Institute (CMCRC/RI) (Bentivoglio, Italy) in accordance with the rules of Italian law for Animal Welfare 
(Decreto Legislativo 26, 2014), following the principles of Good Laboratory Practices and Standard Operating 
Procedures of the CMCRC/RI facility, which include authorization by the ethical committee. At Mount Sinai, the 
study was approved by the Institutional Animal Care and Use Committee (IACUC). The experiment used female 
Sprague-Dawley (SD) rats which belong to the colony that has been used for over 40 years in the laboratory of the 
CMCRC/RI. There were no siblings in each treatment group and they were randomized so as to have minimal 
differences in body weight among them (standard deviation <10% of the average). Animals were housed in mak-
rolon cages (41 × 25 × 15 cm) at two or three per cage, with a stainless steel wire top and a shallow layer of white 
wood shavings as bedding (Giuseppe Bordignon supplier, Treviso, Italy). All animals were kept in a single room 
at 23 ± 3 °C and 40–60% relative humidity. Lighting was artificial and the light/dark cycles were approximately 
12 hours each. All animals were given the same standard “Corticella” pellet diet (Piccioni Laboratory, Milan, 
Italy). Feed and tap water were available ad libitum and were both periodically analyzed to exclude biological and 
chemical contamination (mycotoxins, pesticides, arsenic, lead, mercury, selenium).
There were four experimental groups: parous and age-matched nulliparous, treated with DEP or vehicle, olive 
oil. There were five animals per experimental group. Animals were weighed weekly to determine treatment dose. 
F0 generation corresponds to breeders of the experimental animals (F1). F1 animals were treated daily from post-
natal day (PND) one to PND 28 through milk of their dams (F0), which were gavaged with DEP or vehicle. After 
weaning at PND 28, F1 animals were treated with DEP or vehicle by gavage three times a week until PND 180 
and sacrificed at PND 181. Parous rats were mated (outbred) at PND 97 and treatment was continued through 
pregnancy, delivery of pups (F2) and lactation. At the time of sacrifice of parous rats on PND 181, F2 pups had 
completed weaning. Animals were euthanized via carbon dioxide inhalation and necropsy was immediately per-
formed for collection of mammary tissues. Animals were sacrificed on the same day and at random during the 
estrous cycle.
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Transcriptome profiling in rats. The fifth left and right caudal mammary glands were collected, pulverized 
in liquid nitrogen and total RNA was extracted using Maxwell 16 LEV simplyRNA Blood kit (Promega, WI) or 
by Direct-zol RNA MiniPrep kit (Zymo Research, CA). RNA concentration was determined using NanoDrop 
(Thermo Scientific, MA) and RNA quality was assessed using a 2100 Bioanalyzer (Agilent Technologies, CA); 
samples with RNA Integrity Number ≥ 7 were used for microarrays. Transcriptomes were profiled by GeneChip 
Rat Gene 2.0 ST arrays (Affymetrix, CA) at the Yale Center for Genome Analysis (Yale School of Medicine, CT) 
as described previously22. Quality control of .CEL files and pre-processing by robust multiarray average (RMA) 
method were done using expression console software (Affymetrix, CA). Batch effects due to RNA extraction 
method were removed using ComBat package23 in RStudio (R 3.0.2). We applied a signal intensity filter to retain 
only those probesets with high and stable expression (signal value >30th percentile in at least one experimental 
group). A variance-based filter was used to retain the top 50% of probesets with high interquartile range result-
ing in a final dataset containing 7,532 genes. Microarray data have been deposited in NCBI’s Gene Expression 
Omnibus (GEO) and are accessible through GEO Series accession number GSE95554 (https://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=GSE95554)
Study population. We utilized resources from the Long Island Breast Cancer Study Project (LIBCSP), which 
includes a population-based sample of women newly diagnosed with first primary breast cancer who participated 
in the main study interview within two to three months of diagnosis24. Approval of the Institutional Review Board 
(Program for the Protection of Human Subjects) was obtained by all participating institutions and informed 
consent was obtained from all study participants. Study participants included 1,508 women diagnosed with first 
primary in situ or invasive breast cancer between 1996 and 1997 who resided in Nassau and Suffolk counties on 
Long Island, NY. At the time of the in-person baseline interview, 93% of participants donated 25 mL spot urine 
samples, which were shipped overnight on ice, processed, and banked at −20 °C. Archived tumor tissue of the 
first primary breast cancer was obtained from the diagnosing hospitals25. Demographic, reproductive and lifestyle 
characteristics of women with available pre-malignant adjacent tissue and urinary MEP concentrations (n = 294), 
are provided in Table 1.
Tumor tissue was excised prior to treatment initiation. Formalin-fixed, paraffin-embedded (FFPE) tumor 
sections were histopathologically reviewed by a trained pathologist and the cancer tissue was separated using 
manual microdissection for 745 women, and histologically normal pre-malignant adjacent tissue was retrieved 
for 586 of them. Following RNA extraction and quality control, samples were cross-referenced with DEP expo-
sure information to obtain the final number of samples used in this study: 294 pre-malignant adjacent tissues, of 
which 243 had a paired tumor tissue.
Monoethyl phthalate (MEP) was measured in spot urine samples donated by 892 women with breast cancer 
using standard laboratory techniques by staff at the Centers for Disease Control and Prevention. Briefly, metabo-




Age at diagnosis: mean (SD) 57.9 (12.7) 59.3 (12.8)
Stage = invasive (%) 262 (89.1) 768 (86.1)
Race = white (%) 274 (93.2) 835 (93.6)
Menopausal status = postmenopausal (%) 189 (65.6) 605 (67.8)
Parity = 1 or more (%) 254 (86.4) 769 (86.2)
Lactated (%) 96 (32.7) 292 (32.7)
Age at menarche: mean (SD) 12.6 (1.6) 12.5 (1.6)
Age at first birth: mean (SD) 25.7 (4.8) 25.7 (4.9)
Oral contraceptive use (%) 141 (48.0) 377 (42.3)
Hormone replacement therapy use (%) 82 (28.0) 246 (27.6)
Current or past smoker (%) 165 (56.1) 485 (54.3)
Alcohol (%) 180 (61.2) 556 (62.3)
BMI: mean (SD) 26.9 (6.1) 26.9 (5.8)
Education:
        ≤High School 142 (48.5) 443 (49.8)
        College 112 (38.2) 316 (35.5)
        Post-college 39 (13.3) 131 (14.7)
Income:
        ≤$24,999 50 (19.5) 175 (22.2)
        $25,000-$49,999 90 (35) 237 (30.2)
        ≥$50,000 117 (45.5) 374 (47.6)
Table 1. Participant characteristics. All LIBCSP women with urinary MEP measurements (n = 892) compared 
with subset with both urinary MEP measurement and DEP gene signature measurement in pre-malignant 
adjacent tissues (n = 294).
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extraction, and instrumental analysis was done with high performance liquid chromatography–tandem mass 
spectrometry using isotope dilution quantification as described before26.
Gene expression profiling in LIBCSP. Genes found to be differentially expressed by DEP exposure 
in rat mammary tissues were converted to orthologous human IDs using the Gene Annotator tool in the rat 
genome database27, resulting in a panel of 107 genes. These genes were included as part of a custom-designed 
code-set (NanoString Technologies, WA) to determine expression of the DEP gene signature in breast tumor 
and pre-malignant adjacent tissues of the LIBCSP. Total RNA was extracted from FFPE breast tumor and adja-
cent tissues using the Qiagen miRNeasy FFPE kits (Qiagen, MD). RNA concentration and quality were deter-
mined using NanoDrop (Thermo Scientific, MA). Only those samples exceeding concentration of 10 ng/µL were 
used. 100 ng RNA was incubated with reporter and capture probes overnight at 65 °C. Following hybridization, 
unbound probes were removed, and the purified complexes were aligned and immobilized on imaging cartridges 
using an nCounter Prep station. Code count detection was carried out by scanning cartridges in an nCounter 
Digital Analyzer to determine gene expression levels. Raw nCounter code counts were first normalized against 
the geometric mean of spike-in control probes to minimize the impact of sample preparation and detection. 
For background determination, counts that fell below two standard deviations of the mean of negative control 
probes were deemed unexpressed and assigned a value equivalent to the background threshold divided by the 
square root of two. Finally, data were normalized against the geometric mean of 6 housekeeping genes with high 
and stable expression: CLTC, GAPDH, GUSB, HPRT1, PGK1 and TUBB. The final dataset was log2 transformed.
Statistical methods. Differential gene expression analysis in rats. Differential gene expression analysis 
between DEP and control in rats was performed using linear models for microarray data (limma) package28. To 
obtain a robust DEP gene signature, we bootstrapped samples by choosing four out of five samples in treatment 
groups and in control groups resulting in 25 rounds of differential gene expression analysis each for parous and 
for nulliparous groups. A lenient false discovery rate (FDR) of 25% using Benjamini-Hochberg (BH) correction29 
and a fold change of ≥1.5 fold was used. For functional enrichment analysis of differentially expressed genes we 
used gene ontology (GO)30 via EnrichR31. Fisher’s exact test32 was used to assess significance of enrichment at a 
FDR of 5% by BH method.
Signature gene analysis in the LIBCSP. Gene expression data of pre-malignant adjacent tissues as well as urinary 
MEP concentration were available for 294 breast cancer cases. Examination of the association between urinary 
MEP concentration and expression of each gene in the DEP gene signature was carried out using generalized 
linear models33 before and after stratifying by menopausal status. Natural log transformed urinary MEP con-
centration was quartiled, and the median of each quartile was considered as the predictor. To reduce the dimen-
sionality of the dataset, we performed factor analysis to group highly correlated genes into latent factors using 
the psych package34 with a correlation cutoff of 0.3 to load a gene into a factor. We subsequently carried out an 
examination of the association between quartiles of urinary MEP concentration with the latent factors, such as 
oral contraceptive use, hormone replacement therapy, lactation, smoking status, religion etc. Differential gene 
expression analysis between pre-malignant adjacent and corresponding tumors in this study (n = 243) as well as 
in the breast cancer TCGA microarray data (n = 61 tumors and adjacent samples) filtered to include only the DEP 
gene signature, was carried out using Wilcoxon signed rank test35. To gain insight about upstream molecular reg-
ulators of genes contained within factors, we performed enrichment for transcription factors using ‘ChEA 2016’ 
via Enrichr31 which uses Fisher’s exact test32. Multiple comparisons were adjusted using BH-based FDR of 5%.
A full analysis of the association between phthalate exposure and breast cancer incidence in the LIBCSP cases 
and population-based controls has been reported previously13.
Ethics approval and consent to participate. Animal studies were performed following the principles of 
Good Laboratory Practices and Standard Operating Procedures of the CMCRC/RI facility, which include author-
ization by the ethical committee; the study was approved by the Institutional Animal Care and Use Committee 
(IACUC) of Mount Sinai. For the Long Island Breast Cancer Study Project (LIBCSP), Institutional Review Board 
approval was obtained by all participating institutions and informed consent was obtained from all study par-
ticipants; study was approved by the Institutional Review Board of Mount Sinai (Program for the Protection of 
Human Subjects). All experiments were performed in accordance with relevant guidelines and regulations.
Results
Identifying a DEP gene signature in rats. Our final dataset of ~7,500 genes was obtained after filtering 
the mammary microarray data to retain only those genes with both high expression and variation. We then per-
formed differential gene expression analysis between DEP-treated rats and controls to identify a phthalate gene 
signature. To identify a robust signature, we bootstrapped samples in parous and nulliparous rats separately given 
the potential difference in mammary transcriptome. This resulted in 339 and 43 differentially expressed genes 
by DEP treatment in the parous and nulliparous rat groups, respectively. For the parous rat group, we ranked 
genes by their difference in median expression between treatment and control and selected the top 100 genes. 
Finally, we identified the human orthologs of the rat genes resulting in 91 orthologous human genes in the parous 
group (‘DEP parous gene signature’) and 34 orthologous human genes in the nulliparous group (‘DEP nulliparous 
gene signature’) (Supplementary Table 1). These gene signatures separated DEP-treated from the control groups 
(Fig. 1A,B). All genes in both parous and nulliparous signatures were down-regulated by DEP exposure, except 
for Rps16 which was up-regulated in the nulliparous rat group. Eighteen genes overlapped between the parous 
and nulliparous signature, resulting in a final gene panel of 107 genes (‘DEP gene signature’) (Fig. 1C). Pathway 
enrichment analysis of these 107 genes revealed enrichment of gene ontology (GO) terms ‘mammary gland 
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alveolus development’ (TPH1, AREG, PRLR), ‘response to hypoxia’ (MUC1, ACAA2, CLDN3, TGFB3, ALDOC, 
ANGPTL4, CD24, TLR2), ‘response to steroid hormone’ (FOXA1, SLC34A2, AR, KRT19, TGFB3, PTGDS, CD24, 
AREG, TLR2, ABCG2) and ‘cellular amine metabolic process’ (SLC44A3, TPH1, SLC44A4, AADAT, PLA2G2A, 
MBOAT1) (FDR < 0.05).
DEP gene signature in humans. Among the LIBCSP case cohort, we have 294 subjects with both gene 
profile and urinary MEP measurement. We compared the full group of cases with urinary MEP information 
(n = 892) with the subset (n = 294) used in our investigation and found no major differences in clinical, demo-
graphic and reproductive factors (Table 1), nor did we detect any difference in MEP distribution between the two 
groups (Fig. 2).
We examined the expression of the 107 DEP gene signature in pre-malignant adjacent breast tissues and found 
that 85 out of the 107 genes were consistently expressed in over 75% of the 294 tissues examined. Univariate 
analyses were used to test the association between the expression of these 85 genes with quartiles of urinary MEP 
using generalized linear models. Overall, four genes were significantly associated with MEP (AREG, TMEM50B, 
CA8, C4ORF19) regardless of menopausal status. Given the different risk factor profiles associated with pre- and 
postmenopausal breast cancer36–38 we stratified our analysis by menopausal status and found that nine and three 
genes were significantly associated with MEP in the pre-malignant adjacent breast tissue among postmenopau-
sal (n = 189) and premenopausal (n = 99) women, respectively (p < 0.05, Table 2, Fig. 3A). In postmenopausal 
women, six genes (AREG, TMC4, MPZL3, P4HA1, CA8, PLEKHA6) had decreasing expression with increasing 
levels of MEP, which was consistent with results from rats where we observed reduced gene expression levels with 
DEP exposure. Given the limited sample size in premenopausal women, we carried out subsequent analysis in 
Figure 1. DEP gene signatures in adult (A) parous and (B) age-matched nulliparous Sprague-Dawley 
rats identified by limma analysis of bootstrapped samples (FDR < 0.25, fold change ≥1.5). (C) Overlap of 
parous and nulliparous gene signatures. A full list of gene names in each group is provided in Supplemental 
Information (Table S1).
Figure 2. Comparative density distributions of monoethyl phthalate (MEP) concentrations between all samples 
with urinary MEP concentration (n = 892) and subset of samples with both MEP concentration and DEP gene 
signature measurement in pre-malignant adjacent breast tissues (n = 294) among LIBCSP case women.
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postmenopausal women only. To reduce multiple comparisons and to take advantage of the strong correlation 
structure among genes, a dimensionality reduction technique, i.e. factor analysis, was carried out (Fig. 4). Factor 
analysis revealed seven loading factors among the genes in the DEP gene signature (Table 3), of which one of the 
factors, factor #2, was inversely associated with urinary MEP (p < 0.05, Fig. 3B). The six genes that were iden-
tified to be inversely associated with urinary MEP in univariate analysis loaded onto factor #2. We performed 
transcription factor enrichment analysis of all 20 genes that loaded into factor #2 to identify putative upstream 
molecules that may regulate these genes. Results revealed enrichment for several transcription factor binding sites 
including SOX2, AR, GATA1, FOXA1 and TBX20 among these genes (p < 0.05, Table 4). Genes contributing to 
enrichment of androgen receptor (AR) included SLC44A3, P4HA1, CXADR, AADAT, GALNT3 and ABCG2. We 
then restricted our analysis to AR + cases, which we defined as AR expression above the lower whisker of Tukey’s 
boxplot39 (n = 167) and found six more genes to be inversely associated with urinary MEP (Table 2).
We compared expression levels of 107 DEP signature genes in adjacent and their tumor counterparts (n = 243 
pairs), and found that 33 genes were down-regulated and 34 genes were up-regulated in adjacent compared to 
corresponding tumor tissues at FDR < 0.05 (Fig. 5). In particular, all six genes found to be inversely associated 
with urinary MEP in adjacent tissues among postmenopausal women were also down-regulated in adjacent 
All (n = 294) P-value Beta
Postmenopausal 
(n = 189) P-value Beta
Postmenopausal with 
high AR expression 
(n = 167) P-value Beta
Premenopausal 
(n = 99) P-value Beta
AREG 0.014 −0.14 AREG 0 −0.22 AREG 0 −0.244 HMGCS2 0.006 0.41
TMEM50B 0.026 0.07 TMC4 0.008 −0.23 SLC5A3 0.002 0.124 CLDN8 0.023 0.26
CA8 0.03 −0.11 TMEM50B 0.008 0.11 SPINT1 0.008 −0.117 MUC1 0.039 0.22
C4ORF19 0.045 0.13 MPZL3 0.013 −0.17 NAT8L 0.01 0.262
P4HA1 0.014 −0.18 TSPAN1 0.011 −0.284
CA8 0.015 −0.16 P4HA1 0.015 −0.186
SLC5A3 0.034 0.09 TACSTD2 0.015 −0.137
PLEKHA6 0.039 −0.15 TMC4 0.016 −0.22







Table 2. Association between DEP gene signature and MEP concentration in pre-malignant adjacent breast 
tissues (p < 0.05) among LIBCSP case women.
Figure 3. (A) Association between DEP gene signature and MEP concentration in pre-malignant adjacent 
breast tissues among postmenopausal women (n = 189; p < 0.05). (B) Association between factor 2 and MEP 
concentration (p < 0.05). Points on graph depict mean +/− standard error.
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tissues compared to paired tumors. Results on four of these genes (P4HA1, TMC4, MPZL3, PLEKHA6) were also 
validated in the TCGA dataset (FDR < 0.05); however, AREG and CA8 showed the opposite trend.
Discussion
In the present study, we identified a DEP-induced gene signature using a rodent model and translated it 
to a population-based sample of women newly diagnosed with primary breast cancer, who had available 
pre-malignant adjacent and tumor tissue. To our knowledge, this is the first study of its kind to translate animal 
data to humans in an appropriate target tissue using a DEP dose relevant to human exposure. Rats have been 
widely used to study breast cancer since the pre-malignant stages of mammary cancer in rats closely recapitulate 
the human disease40.
We first identified a panel of 107 genes modified by DEP exposure in rats treated chronically from birth to 
adulthood using a human-level exposure that has previously been shown to result in urinary MEP concentra-
tions within the range reported for the U.S. population17. By bootstrapping samples to overcome the limitation 
of small sample size for each experimental group (n = 5), we were able to show that even at a low, human level 
exposure, measurable changes in the transcriptome were detectable. The 107 modified genes in adult rats were 
predominantly down-regulated by DEP exposure and were enriched for biological processes such as ‘mammary 
gland alveolus development’. Interestingly, overexpression of at least eight genes among the DEP gene signature 
has been previously reported in breast cancer tissues; these include the genes FOXA141, PRLR42, TPH143, AREG44, 
AR45, XBP146, TGFB347 and HMGCS248. Coordinated down-regulated expression of these genes by DEP exposure 
in our study seemed to suggest an inverse relationship between DEP and breast cancer in animal models. While 
we could not obtain such information in our animal study (all rats were sacrificed by PND 181, which is too early 
for spontaneous tumor formation to occur), the suggestive inverse association in our population study13 seems to 
corroborate this postulation.
We next examined the DEP gene signature in pathologically non-malignant tissues because we hypothesized 
that gross genomic abnormalities in tumor tissues would mask the likely subtle effects of low-dose environ-
mental chemical exposures. In particular we identified by univariate analysis, a subset of six out of 107 genes to 
be negatively associated with urinary MEP in pre-malignant adjacent tissues of postmenopausal women. The 
Figure 4. Correlation structure of DEP gene signature in pre-malignant adjacent breast tissues among LIBCSP 
postmenopausal women, where genes are ordered by factors as indicated by numbers on top of figure.
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down-regulated expression of these six genes with urinary MEP in humans was consistent with direction of 
expression change observed in rats by DEP exposure. These six genes have diverse functions. P4HA1 encodes 
a component of prolyl 4-hydroxylase, a key enzyme in collagen synthesis; it was shown to be an activator of the 
HIF-1 pathway in breast cancer and biomarker of poor prognosis in various types of cancers including melano-
mas49, pancreatic cancer50 and head and neck squamous cell carcinomas51. MPZL3 (Myelin protein zero like 3) is 
involved in mediating cell adhesion but little is known about its possible role in cancer pathways. TMC4 encodes 
a transmembrane channel protein52; while its expression was upregulated in tumor-versus-adjacent tissue in our 
dataset as well as TCGA, other studies reported its downregulation in high-metastatic breast cancer cell lines 
compared to their low metastatic counterparts53 as well as breast-cancer cells compared to normal breast epi-
thelium54, and its increased expression in tumors was associated with better survival of breast cancer patients55. 
PLEKHA6 (Pleckstrin Homology Domain Containing 6) has been shown to be differentially methylated in head 
and neck cancer56; its high expression was shown to be a positive prognostic factor in lung57 and breast55,58 can-
cers. CA8 (Carbonic Anhydrase 8) encodes an inhibitor of inositol trisphosphate inhibitors which regulate intra-
cellular calcium release fundamental to many cellular processes including mitochondrial energy production and 
cell fate59. AREG (Amphiregulin) is a member of the epidermal growth factor family that is expressed in the 
mammary gland during development and has been shown to promote the growth of normal epithelial cells while 
inhibiting the growth of aggressive carcinoma cell lines52.
The strong correlation structure underlying genes in adjacent tissues enabled us to use factor analysis to derive 
seven factors, clusters of highly correlated genes, of which one factor, factor 2, showed independent negative asso-
ciation with urinary MEP. Interestingly, all six genes identified by univariate analysis loaded into factor #2, indi-
cating similar expression patterns of these genes. Furthermore, we showed that the six genes that were negatively 
associated with urinary MEP were also coordinately down-regulated in adjacent compared to paired tumor tissue, 
and four out of six of these genes were also down-regulated in adjacent compared to paired tumors of the TCGA 
dataset. Collectively, our results from humans and animals seem to suggest an inverse relationship between DEP 
Factor Genes loading onto factor
Factor 1 FOXA1,AR,KRT19,TMEM50B,CBLC,TMEM30B,KRT18,PRSS8,WFDC2,ST6GALNAC2,MUC1,NAT8L,TGFB3,FAM134B,ICA1,HMGCS2,TFAP2B








Table 3. Factor analysis of DEP gene signature in pre-malignant adjacent breast tissues among postmenopausal 
women revealed 7 latent factors. Genes in bold are those that were significant at p < 0.05 from univariate 
analysis (Fig. 3), many of which load onto factor 2.
Transcription 
Factor Contexta Species P-valueb
Adjusted 
P-value
SOX2 SW620 Human 0.000 0.187
AR LNCAP Human 0.003 0.340
SOX2 STOMACH Mouse 0.011 0.519
FOXA1 ENDOMETRIOID-ADENOCARCINOMA Human 0.020 0.564
GATA1 MEL Mouse 0.031 0.623
AR VCAP Human 0.036 0.623
TBX20 HEART Mouse 0.043 0.623
TBX20 HEART Mouse 0.043 0.623
GATA1 MEL86 Mouse 0.043 0.623
FOXA1 PDAC Human 0.043 0.623
Table 4. Transcription factor enrichment analysis of genes in factor #2 using ChIP-X Enrichment Analysis 
(ChEA) database via EnrichR. aRefers to cell-line or tissue in which the experiment was done. bThe p-value 
is computed from a Fisher’s exact test (FET), a proportion test that assumes a binomial distribution and 
independence for probability of any gene belonging to any gene-set. The top 5 transcription factors that 
appeared at least twice with a p-value < 0.05 are shown. ChEA is a gene-set enrichment analysis tool that tests 
if query gene-sets are enriched with genes that are putative targets of transcription factors, utilizing a gene-set 
library of transcription factors and their putative target genes curated from published ChIP-chip, ChIP-seq, and 
similar experiments (Lachmann et al. 2010).
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exposure and breast cancer development. However, we acknowledge the cross-sectional nature of our study, 
where urinary MEP concentrations were obtained only at one time-point after breast cancer diagnosis, and may 
not necessarily reflect lifetime exposure to DEP or whether the exposure occurred prior to diagnosis of breast 
cancer. Additionally, there is no control (cancer-free) population in the study. Hence, whether phthalate-induced 
transcriptome changes modify breast cancer susceptibility needs to be further investigated to clarify the etiologic 
mechanism of phthalates in breast carcinogenesis. Design of the current study does not allow us to claim the 
direct link between DEP exposure and breast cancer risk. We also have to acknowledge a seeming discrepancy 
of our results with the studies of López-Carrillo et al.10 (higher urine levels of MEP associated with increased BC 
risk) and Sprague et al.11 (elevated serum levels of MEP associated with increased breast density) for which we 
currently don’t have an explanation.
To gain insight about upstream molecular regulators of genes associated with urinary MEP in postmenopausal 
tumor-adjacent breast tissues, we performed transcription factor enrichment analysis of the 20 genes belong-
ing to factor 2 and observed enrichment for AR binding sites among these genes. The anti-androgenic activity 
of phthalates has been extensively reported, which include endpoints such as shorter anogenital distance and 
reduced testosterone levels5,60–62. While the mechanism of anti-androgenic activity of phthalates has been shown 
to be mediated by inhibition of testosterone synthesis leading to Leydig cell dysfunction62,63, several phthalates 
have been shown to be able to bind to AR weakly suggesting that phthalates may elicit their effects through both 
receptor- and non-receptor-mediated pathways64. Even though in our study AR was among the signature panel of 
genes disrupted by DEP in rats, its expression was not significantly altered with urinary MEP exposure in human 
tissues. However, we noted that among postmenopausal women with high AR expression, six more genes were 
significantly associated with urinary MEP, suggesting that AR could play a role in the association between phtha-
late exposure and gene expression.
Our results indicated stronger associations of DEP signature genes among adjacent tissues of postmenopau-
sal women, and not premenopausal women; part of this could be attributed to the smaller sample size among 
premenopausal (n = 99) compared to postmenopausal (n = 189) women. Premenopausal breast cancers tend 
to be more aggressive36, be associated with poorer survival37 and have distinct molecular profiles compared to 
postmenopausal breast cancers38. There was no major difference in distribution of MEP concentrations between 
premenopausal and postmenopausal women in our dataset. Whether there are different environmental etiologies 
of premenopausal compared to postmenopausal breast cancers remains to be elucidated.
We found a larger number of genes modified among parous rats (339 genes) compared to nulliparous rats 
(43 genes) suggesting that parity may play a role in modifying the effects of phthalate exposure on the mammary 
gland transcriptome. The parous rats in our study completed pregnancy and lactation and were sacrificed 35 
days after the end of lactation. Post-lactational involution occurs within a few days of end of lactation whereby 
apoptosis of secretory structures remodels the gland to its pre-pregnant ductal architecture resembling its virgin 
Figure 5. Genes significantly differentially expressed between paired tumor and adjacent breast tissues among 
LIBCSP postmenopausal women (FDR < 0.05). Blue indicates down-regulation and red indicates up-regulation 
in pre-malignant compared to tumor, respectively. Labels indicate genes found to be associated with MEP 
concentration (see Table 2).
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counterpart65. That we did not observe significant gene expression changes between parous and nulliparous rats 
suggests that the parous rats in our study had finished involution. Parity is known to reduce the risk of develop-
ing breast cancer66; however how environmental factors interact with parity to influence cancer susceptibility is 
unknown. Our results suggesting that phthalate exposure had a more profound effect on the transcriptome of 
parous compared to nulliparous rats warrants further investigation, for example, by examining rates of spontane-
ous mammary tumor formation among exposed and control groups later in life.
We acknowledge some limitations of our study. First is the translation of findings from rats to humans. While 
rats have been a useful model system to study breast cancer, important species-specific differences exist, includ-
ing an accelerated lifespan leading to condensed mammary developmental timing in rats, six pairs of mammary 
glands in rats compared to one in humans67 as well as species-specific differences in response to environmental 
chemicals68. Nevertheless, Sprague-Dawley rats have been shown to be one of the most physiologically relevant 
and genetically defined animal models for studying human sporadic breast cancer69,70. For example, they share 
similar age-equivalent distribution of mammary tumors as in human population; mammary carcinomas from 
this animal model also share many morphological and molecular features, including estrogen-dependence, 
chromosomal instability, aneuploidy, and deregulation of cell cycle with breast cancer in human populations71. 
Additionally, we did not have a technical possibility to run additional assays such as in situ hybridization exper-
iments or immunohistochemical staining to confirm the expression changes in the caudal mammary glands. 
Second is the translation of findings from normal mammary glands in rats to cancer-adjacent breast tissues in 
humans. Extratumoral benign-appearing tissues lying adjacent to breast tumors have been shown to harbor 
genomic alterations such as somatic loss of heterozygosity, methylation changes and shortened telomeres, and 
in some cases may have been infiltrated with tumor cells72 – the so-called “field effect” – making it harder to 
untangle the subtle effects of low-dose environmental chemical exposures on transcriptome pattern. Finally, the 
route of exposure used in animal studies involved oral gavage, while exposures to many environmental chemicals, 
including phthalates have been shown to occur via multiple routes other than oral, such as dermal or by inha-
lation62. However, we attempted to resolve this issue by calibrating the exposure dose to achieve similar urinary 
biomarker concentration in rats and humans.
Conclusion
Using an integrative and translational approach, we identified a DEP gene signature in an animal model which 
was partially validated in a human population. Functional relevance of the gene signature indicated by in silico 
pathway analysis further support the potential causal role of phthalate in breast carcinogenesis.
Data availability
Microarray data have been deposited in NCBI’s Gene Expression Omnibus (GEO) and are accessible through 
GEO Series accession number GSE95554.
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